Company Filing History:
4 out of 151 
1 out of 1,179 
Years Active: 2017-2021
Title: Innovator Spotlight: Werner Höllriegl
Introduction
Werner Höllriegl, an accomplished inventor based in Altenmarkt/Triesting, Austria, has made significant contributions to the field of medical innovation. With two registered patents to his name, Höllriegl has focused on advancing therapies that target critical health conditions associated with ADAMTS13 and von Willebrand Factor (VWF) dysfunction.
Latest Patents
Höllriegl's most notable patents include methods for the subcutaneous administration of ADAMTS13 formulations. These inventions provide innovative approaches to treating diseases linked to ADAMTS13, showcasing evidence of unexpectedly high bioavailability when the formulations are administered subcutaneously. This development holds promise for improving the efficacy of treatments for patients with related conditions.
Career Highlights
Currently, Höllriegl is employed at Baxalta GmbH. His work within this company highlights his commitment to harnessing innovation in therapeutic applications, emphasizing the importance of finding better methods to deliver necessary treatments in the healthcare sector.
Collaborations
Throughout his career, Höllriegl has collaborated with talented coworkers, including Alexandra Nathalie Kopic and Barbara Plaimauer. These partnerships have proven essential in driving forward the research and development processes underlying his patented innovations.
Conclusion
With his focus on groundbreaking methodologies in medical treatments, Werner Höllriegl stands out as a significant figure in the world of inventions and patent innovation. His work, especially regarding ADAMTS13 formulations, continues to pave the way for advancements that could benefit many patients in need of effective therapies.